A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib

Sponsor
University Health Network, Toronto
Study ID
NCT02340611
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Olaparib — DRUG
    Polyadenosine 5'diphosphoribose polymerase (PARP) Inhibitor
  • Cediranib — DRUG
    Vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor that is a potent inhibitor of all three VEGF receptors (VEGFR-1, -2 and -3)

Study Details

This is a phase 2 study (the second phase in testing a new drug or drug combination) to see how useful adding investigational drug cediranib to olaparib after disease progression on olaparib alone in patients with ovarian cancer.

Key Dates

Start date
Jun 30, 2015
Status verified
Jun 2018
Primary completion
Jun 30, 2018
Completion
Jun 30, 2018

Study Design

Enrollment
4 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cediranib and Olaparib
    Cediranib, 20 mg , orally, once a day, every day. Olaparib, 150 mg or 200 mg (depending on previous treatment dose), orally, once a day, every day.

Primary Outcome Measure

Percentage of patients whose cancer shrinks or disappears after treatment [ Time Frame: 2 years ]

Related Studies